United Therapeutics Corporation Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
United Therapeutics Corporation (UTHR) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax of $5.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax · last filed 2026-02-25
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2025 was $5.60M, a 5.66% increase from fiscal 2024.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2024 was $5.30M, a 55.88% increase from fiscal 2023.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2023 was $3.40M.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2022 was -$20.40M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 12 month |
|---|---|
| 2025-12-31 | $5.60M 10-K · filed 2026-02-25 |
| 2024-12-31 | $5.30M 10-K · filed 2026-02-25 |
| 2023-12-31 | $3.40M 10-K · filed 2026-02-25 |
| 2022-12-31 | -$20.40M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$6.50M 10-K · filed 2024-02-21 |
| 2020-12-31 | $7.10M 10-K · filed 2023-02-22 |
| 2019-12-31 | $13.30M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |